Eli Lilly strengthens GI focus through $3.2B acquisition

Pharmaceutical company Eli Lilly plans to acquire Morphic, a biopharmaceutical company that specializes in treating gastroenterology patients, for $3.2 billion. 

Morphic's lead program is an oral treatment for inflammatory bowel disease patients, according to a July 8 news release. 

The molecule is also being evaluated to treat patients with ulcerative colitis and Crohn's disease. 

The transaction has been approved by the boards of directors of both com

Subscribe to the following topics: 1 pharmaceutical company2. eli lilly3. acquire4. morphic5. biopharmaceutical company6. gastroenterology patients7. inflammatory bowel disease8. $3.2 billion

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like